Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
about
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population.The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis.YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
P2860
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasma YKL-40 in patients with ...... ULTS from the NORDIC VII Study
@en
Plasma YKL-40 in patients with ...... LTS from the NORDIC VII Study.
@nl
type
label
Plasma YKL-40 in patients with ...... ULTS from the NORDIC VII Study
@en
Plasma YKL-40 in patients with ...... LTS from the NORDIC VII Study.
@nl
prefLabel
Plasma YKL-40 in patients with ...... ULTS from the NORDIC VII Study
@en
Plasma YKL-40 in patients with ...... LTS from the NORDIC VII Study.
@nl
P2093
P2860
P1433
P1476
Plasma YKL-40 in patients with ...... ULTS from the NORDIC VII Study
@en
P2093
Bengt Glimelius
Elin H Kure
Halfdan Sorbye
Ib J Christensen
Julia S Johansen
Kjell Magne Tveit
Mette Yilmaz
Tone Ikdahl
Tormod K Guren
P2860
P304
P356
10.1371/JOURNAL.PONE.0087746
P407
P577
2014-02-03T00:00:00Z